InventisBio Co., Ltd

Quick facts

Phase 3 pipeline

• D-0502 · Oncology
  D-0502 is a small molecule that targets the molecular target.
• D-1553 · Oncology
  D-1553 is a small molecule that targets the PI3K/AKT/mTOR pathway.
• D-2570 · Oncology
  D-2570 is a small molecule that targets the PI3K/AKT pathway.

Phase 2 pipeline

• D-0120 · Immunology
  D-0120 is a small molecule inhibitor of the PI3K delta subunit.

Phase 1 pipeline

• [14C]-D-0502
• [14C] D-1553
• [14C] D-2570 group
• D-0120 in combination with Allopurinol

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• InventisBio Co., Ltd portfolio CI brief
• InventisBio Co., Ltd pipeline updates RSS